Serum analysis confirmed YCHD’s hepatoprotective effects, with dose-dependent reductions in cholestasis biomarkers (ALT, AST, ALP, TBIL, DBIL, TBA) to near-normal levels (Figure 1F). Here, GPT is linked to cholestasis.